Case Reports

High-grade leiomyosarcoma of the transverse colon presenting with bowel perforation


 

Stromal or mesenchymal tumors account for about 1% of gastrointestinal (GI) tract neoplasms and are divided into 2 main categories: the gastrointestinal stromal tumors (GISTs; 60%- 90% of mesencymal tumors), and the non-GIST neoplasms (10%-30% of mesencymal tumors).1 The non-GIST neoplasms consist of a heterogenous group of soft-tissue tumors, identical to soft-tissue tumors elsewhere in the body.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Immunosuppressive regimens did not affect risk of cancer recurrence in meta-analysis
MDedge Hematology and Oncology
Esophagectomy 30-day readmission rate pegged at 19%
MDedge Hematology and Oncology
Endorectal balloons decrease prostate radiation’s rectal and bowel sequelae
MDedge Hematology and Oncology
Delaying surgery for 11 weeks after RCT does not increase pCR rates for rectal cancer
MDedge Hematology and Oncology
ASTRO updates treatment standard for rectal cancer
MDedge Hematology and Oncology
Study shows faster increase in obesity prevalence among cancer survivors
MDedge Hematology and Oncology
Oxaliplatin boosts pCR in patients with locally advanced rectal cancer
MDedge Hematology and Oncology
Lentinan missed primary endpoint in gastric cancer trial
MDedge Hematology and Oncology
Inflammatory markers did not significantly predict colorectal cancer risk in men
MDedge Hematology and Oncology
Anal cancer in HIV-infected patients: to screen or not?
MDedge Hematology and Oncology